Much of the research in optimizing anticoagulant therapy for acute VTE has been carried out in patients without malignancies. Given the aggressive natural history of VTE in cancer patients ...

The number of patients who require maintenance on anticoagulation therapy (warfarin/Coumadin ®) for minimizing risk of cardiovascular events like stroke or thromboembolism is increasing.

A new study published in the journal of Molecular Psychiatry found that heparin medication was linked to a delayed diagnosis ...

Participation Reinforces Cadrenal's Commitment to Innovation, Education and Improved Patient Outcomes with Anticoagulation Therapy PONTE VEDRA, Fla., Oct. 23, 2024 /PRNewswire/ -- Cadrenal ...

Anticoagulants slow down the body's process ... risks while benefiting from the protective effects of antiplatelet therapy.

Participants were survivors of acute ischemic strokes likely related to their Afib. In the hospital stroke unit, they were ...

No matter whether patients had CAD or not, the simpler regimen was linked to less mortality and major bleeding at 6 months.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Left atrial appendage occlusion vs continuation of oral anticoagulation therapy alone is linked to reduced ischemic stroke risk in select patients with nonvalvular AF.

UK: In a recent study known as OPTIMAS, researchers have found that initiating direct oral anticoagulants (DOACs) within four ...

Cadrenal Therapeutics, Inc., (Nasdaq: CVKD) (the "Company" or "Cadrenal"), a late-stage biopharmaceutical company developing tecarfarin, a new vitamin K antagonist (VKA) designed to provide safer and ...